Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

April 25, 2019

Primary Completion Date

December 6, 2019

Study Completion Date

June 9, 2021

Conditions
Neoplasms
Interventions
DRUG

Rucaparib

Rucaparib 600 mg BID commencing on Day 5 until Day 23.

DRUG

Rosuvastatin

Single dose of 20mg oral rosuvastatin on Day 1 and Day 19 only.

DRUG

Oral Contraceptives

Single dose of combined oral contraceptive (30 μg ethinylestradiol and 150 μg levonorgestrel) on Day 1 and Day 19 only.

Trial Locations (7)

1076

PRA Magyarország Fázis I-es Klinikai Farmakológiai Vizsgálóhely FMC Dialízis Központ, II. em., Budapest

21-500

Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej, Biała Podlaska

05-410

BioVirtus Centrum Medyczne, Józefów

31-752

Ujastek Sp. z o.o. Centrum medyczne, Krakow

60-693

Med Polonia Sp. z o.o., Poznan

01-401

Zdrowie Kobiety Centrum Leczniczo-Rehabilitacyjne i Medycyny Pracy ATTIS Sp. z o.o., Zakład Onkologii Kobiecej, Warsaw

831 01

Summit Clinical Research s.r.o., Bratislava

All Listed Sponsors
lead

pharmaand GmbH

INDUSTRY

NCT03954366 - Drug-Drug Interaction Study of Rucaparib, Rosuvastatin and Oral Contraceptives | Biotech Hunter | Biotech Hunter